ATCC and Synthego Alliance

Combining the power of gold-standard biomaterials with state-of-the-art gene editing

ATCC and Synthego have entered a strategic alliance to create customized cell models by combining high-quality CRISPR gene-editing services from Synthego with gold-standard, authenticated cell lines from ATCC.

Synthego’s CRISPR platforms leverage an integrated approach to genome editing that combines machine learning, automation, and extensive expertise to deliver high-quality, consistent results at an unprecedented scale. The combination of ATCC's broad selection of high-quality cells and Synthego's Engineered Cells allows researchers to confidently generate assay results and increase their speed to critical data with genome-edited cells in as little as 3 weeks.

What is CRISPR gene editing?

CRISPR is a powerful gene-editing technology that enables scientists to make complex gene edits such as engineered point mutations and gene fusions with more precision, efficiency, and flexibility than ever before. This technology uses a nuclease protein that carries with it an interchangeable short RNA molecule known as guide RNA. The guide RNA directs the nuclease protein to the gene of interest then the nuclease protein cuts the DNA. The cell then tries to repair that damage; during that repair process, the gene sequence at that location can be changed.

Learn more about CRISPR

Take your research to the next level

Below is a selection of cell lines that are currently available for CRISPR gene editing through our partnership with Synthego. To customize these cell lines for your research, visit the Synthego website using the link below and let us know how we can take your research to the next level.

Take me to Synthego's website to customize my cell line

ATCC cell lines currently available for CRISPR editing through Synthego

ATCC Number	Product Name	Organism	Tissue	Disease	Cell Type
HTB-96	U-2 OS	Human	Bone	Osteosarcoma
CCL-243	K-562	Human	Bone; marrow	Chronic myelogenous leukemia
CRL-2003	TF-1	Human	Bone; marrow	Erythroleukemia	Erythroblast
CRL-9068	NCI-H929	Human	Bone; marrow	Plasmacytoma	B lymphocyte
CRL-3304	HMC3	Human	Brain		Microglial cell
HTB-14	U-87 MG	Human	Brain	Likely glioblastoma
CRL-10317	MCF 10A	Human	Breast; mammary gland	Fibrocystic disease	Epithelial cell
HTB-133	T-47D	Human	Breast; mammary gland	Carcinoma; ductal	Epithelial cell
HTB-22	MCF7	Human	Breast; mammary gland	Adenocarcinoma	Epithelial cell
CCL-121	HT-1080	Human	Connective tissue	Fibrosarcoma
CRL-2190	HK-2	Human	Kidney; cortex; proximal tubule	Papilloma
CRL-1573	293 [HEK-293]	Human	Kidney; embryo
CRL-3216	293T	Human	Kidney; embryo
CCL-247	HCT 116	Human	Large intestine; colon	Carcinoma; colorectal
CCL-248	T84	Human	Large intestine; colon	Carcinoma; colorectal
HB-8064	Hep3B2.1-7	Human	Liver	Carcinoma; hepatocellular
HB-8065	Hep G2	Human	Liver	Carcinoma; hepatocellular
CCL-185	A549	Human	Lung	Carcinoma	Epithelial cell
CRM-HTB-174	NCI-H440	Human	Lung	Papillary adenocarcinoma	Epithelial cell
CRL-5807	NCI-H358	Human	Lung; bronchiole	Bronchioalveolar carcinoma, Non small cell lung cancer
HTB-161	NIH:OVCAR-3 [OVCAR3]	Human	Ovary	Adenocarcinoma	Epithelial cell
CRL-1420	MIA PaCa-2	Human	Pancreas	Carcinoma	Epithelial cell
CRL-1682	AsPC-1	Human	Pancreas	Adenocarcinoma
CRL-1687	BxPC-3	Human	Pancreas	Adenocarcinoma
CRL-1469	PANC-1	Human	Pancreas; duct	Epithelioid carcinoma
CCL-155	RPMI 8226	Human	Peripheral blood	Plasmacytoma	B lymphocyte
CCL-240	HL-60	Human	Peripheral blood	Acute promyelocytic leukemia	Promyeloblast
TIB-152	Jurkat, Clone E6-1	Human	Peripheral blood	Acute T cell leukemia	T lymphoblast
TIB-202	THP-1	Human	Peripheral blood	Acute monocytic leukemia	Monocyte
CRL-1593.2	U-937	Human	Pleural effusion	Histiocytic lymphoma
CRL-1435	PC-3	Human	Prostate	Adenocarcinoma; grade IV
CRL-2505	22Rv1	Human	Prostate	Carcinoma	Epithelial cell
HTB-81	DU 145	Human	Prostate	Carcinoma
CRL-1619	A375	Human	Skin	Malignant melanoma
CCL-2	HeLa	Human	Uterus; cervix	Adenocarcinoma	Epithelial cell
CCL-86	Raji	Human		Burkitts lymphoma	B lymphocyte
TIB-71	RAW 264.7	Mouse	Ascites	Abelson murine leukemia virus-induced tumor	Macrophage
CCL-131	Neuro-2a	Mouse	Brain	Neuroblastoma	Neuroblast
CRL-2755	EMT6	Mouse	Breast	Carcinoma; mammary	Epithelial cell
CRL-2539	4T1	Mouse	Breast; mammary gland	Mimics human breast cancer; stage IV
CL-173	3T3-L1	Mouse	Embryo		Fibroblast
CRL-1658	NIH/3T3	Mouse	Embryo		Fibroblast
CRL-2638	CT26.WT	Mouse	Large intestine; colon	Carcinoma	Fibroblast
CRL-1642	LL/2 (LLC1)	Mouse	Lung	Lewis lung carcinoma
CRL-1772	C2C12	Mouse	Muscle		Myoblast
CRL-6475	B16-F10	Mouse	Skin	Melanoma
CRL-1446	H9c2(2-1)	Rat	Heart; myocardium		Myoblast

Take me to Synthego's website

Explore applications of CRISPR-edited cell models

Drug discovery

Gene editing tools such as CRISPR/Cas9 can be used to create isogenic cell lines, which can be further used to model a specific patient population for identifying novel, personalized treatment regimens. Here, an isogenic cell line was created to model cancer patients with the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene—a key oncogenic driver—and then tested for its sensitivity to known selective inhibitors of ALK.

Read the application note

Long, thin, red, ebola rods stuck to a porous black-blue surface.

Virus production

The production of antiviral vaccines is often limited by low-yielding manufacturing processes. Similarly, the development of gene therapies is constrained during the large-scale production of viral vectors, such as adeno-associated virus delivery platforms for gene transfer. To accelerate these areas of bioproduction, we used CRISPR/Cas9 gene-editing technology to develop STAT1 and BAX knockout cell lines capable of producing high-titer viral stocks.

Read the application note

Cancer research

With CRISPR/Cas9 genome-editing technology, we can now engineer cancer models that mimic specific cancer genotypes and phenotypes found in clinical tumor samples. Because these new cancer models are both biologically relevant and biomarker specific, they can greatly enhance the ability of drug developers to identify new compounds and biologics that will perform well in clinical trials and can lead to new developments in targeted cancer therapy.

Learn More